CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort...
PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort...
A study published in Science reveals that a healthy gut microbiota can enhance the efficacy of immunotherapy used to treat...
Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysis...
Leronlimab-mediated CCR5 blockade modulates T-Cell exhaustion pathways and PD-L1 Biology relevant to ICI response Durable Clinical Observations and Favorable Safety...
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement...
Regulatory clearance enables start of clinical testing and marks transition to clinical-stage companyOn track for initial clinical data to emerge...
Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Neck CancerPRINCETON, N.J., Feb. 20, 2026 (GLOBE...
NEW YORK, Feb. 18, 2026 /PRNewswire/ -- A protein made by stressed cancer cells helps lung and pancreatic tumors evade...
NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement...
What is the Market Size of AI in Biotechnology?BANGALORE, India , Feb. 17, 2026 /PRNewswire/ -- According to Valuates Reports, The...
Aiming to introduce a new therapeutic strategy for overcoming chemotherapy resistance in lung cancer due to increased expression of cellular...
Iron-rescue experiments confirm tumor cell mortality is mechanistically driven, not nonspecific cytotoxicity. MIAMI, FL / ACCESS Newswire / February 17,...
Independent DSMB has identified no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune...
London, UK - February 19, 2026BETHESDA, Md., Feb. 13, 2026 /PRNewswire/ -- Precision Biologics, Inc. CEO Philip M. Arlen, MD gives a Keynote...
Jointly developed by China Medical University Hospital and Ever Supreme Bio Technology, the platform demonstrates compelling preclinical tumor clearance across...
Employers nationwide can now offer NCI-designated comprehensive cancer center reviews, clinical trial access, oncology nurse-led navigation teams, and proactive member engagement to...
NEEDHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical...
WHO recognition of “etaroleucel” (CELZ-101) builds on prior “olastrocel” (CELZ-201) milestone, reinforcing platform credibility and supporting multi-program executionPHOENIX, Feb. 10,...
AGOURA HILLS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- via IBN — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the...
Additional exchange listing expected to increase token access and contribute to expanded secondary market liquidity for RAIN Nes-Ziona, Israel, Feb....